Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after west nile virus infection

Muscle and Nerve

Volumn 41, Issue 1, 2010, Pages 42-49

  Petzold, A ^a   Groves, M ^a   Leis, A A ^b   Scaravilli, F ^a   Stokic, D S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b METHODIST REHABILITATION CENTER   (United States)

Author keywords

GFAP; Neurofilaments; Protein biomarker; S100B; West nile virus

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN NFH SMI35; PROTEIN S100B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOSIS; AUTOPSY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; NERVE CELL NECROSIS; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOTOR NEURONS; NEUROFILAMENT PROTEINS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; WEST NILE FEVER;

EID: 73949087519     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21448     Document Type: Article

References (38)

1. Brehin AC, Mouries J, Frenkiel MP, Dadaglio G, Despres P, Lafon M, et al. Dynamics of immune cell recruitment during West Nile encephalitis and identification of a new CD19+B220-BST-2+ leukocyte population. J Immunol 2008; 180:6760-6767.
2. Petersen LR and Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002;137:173-109.
3. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Maculopapular rash and tremor are associated with West Nile fever and neurological syndromes. J Neurol Neurosurg Psychiatry 2007;78:529-31.
4. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344:1807-1814.
5. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006;181-194.
6. Leis AA, Stokic DS. Neuromuscular manifestations of human West Nile virus infection. Curr Treat Options Neurol 2005;15-22.
7. Leis AA, Stokic DS, Webb RM, Slavinski SA, Fratkin J. Clinical spectrum of muscle weakness in human West Nile virus infection. Muscle Nerve 2003;28:302-308.
8. Sejvar JJ, Leis AA, Stokic DS, Van Gerpen JA, Marfin AA, Webb R, et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003;9:788-793.
9. Leis AA, Stokic DS, Polk JL, Dostrow V, Winkelmann M. A poliomyelitis-like syndrome from West Nile virus infection. N Engl J Med 2002;347:1279-1280.
10. Centers for Disease Control and Prevention (CDC).Acute flaccid paralysis syndrome associated with West Nile virus infection - Mississippi and Louisiana, July-August 2002. MMWR Morb Mortal Wkly Rep 2002;51:825-808.
11. Leis AA, Fratkin J, Stokic DS, Harrington T, Webb RM, Slavinski SA. West Nile polymyelitis. Lancet Infect Dis 2003;9-10.
12. Fratkin JD, Leis AA, Stokic DS, Slavinski SA, Geiss RW. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004;128:533-507.
13. Glass JD, Samuels O, Rich MM. Poliomyelitis due to West Nile virus. N Engl J Med 2002;347:1280-1201.
14. Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, Fine A, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004;10:1405-1411.
15. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233:183-198.
16. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41.
17. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-1473.
18. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287:169-177.
19. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190.
20. Green AJE, Keir G, Thompson EJ. A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods 1997;205:35-41.
21. Petzold A, Keir G, Lim D, Smith M, Thompson EJ. CSF and serum S100B: release and wash-out pattern. Brain Res Bull 2003;61:281-285.
22. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190.
23. Hayes EB. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005;11: 1174-1109.
24. O'Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004;4: 61-70.
25. Jeha LE, Hanes GP, Sila CA, Lederman RJ, Carlos I, Steven G. Long-term outcome of patients with West Nile virus infection. Infect Dis Clin Pract 2005;13:101-103.
26. Sindic CJ, Chalon MP, Cambiaso CL, Laterre EC, Masson PL. Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1982;45:1130-1105.
27. Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007;319:34-40.
28. Studahl M, Rosengren L, Gunther G, Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol 2000;247:636-642.
29. Wang T, Fikrig E. Immunity to West Nile virus. Curr Opin Immunol 2004;16:519-523.
30. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:161-264.
31. Centers for Disease Control and Prevention (CDC). Update: surveillance for West Nile virus in overwintering mosquitoes - New York, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:178-109.
32. Centers for Disease Control and Prevention (CDC). Update: West Nile Virus activity - Eastern United States, 2000. MMWR Morb Mortal Wkly Rep 2000;49:1044-1007.
33. Centers for Disease Control and Prevention (CDC). West Nile virus activity - Eastern United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:617-609.
34. Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004;75:1178-1180.
35. Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S, et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker for axonal injury. Biochem Biophys Res Commun 2005;336:1268-1277.
36. van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 2002;326: 151-154.
37. Petzold A, Green AJE, Keir G, Fairley S, Kitchen N, Smith M, et al. Serum S100B in brain injury: an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 2002;30:2705-2710.
38. Lewis SB, Wolper RA, Miralia L, Yang C, Shaw G. Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 2008;28:1261-1271.